Application of reagent for promoting DOCK11 expression as medicine for treating neuropathic pain
The invention discloses application of a reagent for promoting DOCK11 expression as a medicine for treating neuropathic pain. The research finds that mice suffering from neuropathic pain have obvious mechanical abnormal pain and thermal hyperalgesia, and expression of DOCK11 is closely related to mechanical pain and thermal pain of CCI mice. The overexpressed DOCK11 vector can effectively promote the expression of DOCK11 in the spinal cord and obviously inhibit neuropathic pain at the same time. The research results of the invention provide potential therapeutic targets for clinical treatment of neuropathic pain..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Europäisches Patentamt - (2023) vom: 10. Nov. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
LI JING [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-11-10, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26 |
---|
Patentnummer: |
CN117018197 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA003934179 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | EPA003934179 | ||
003 | DE-627 | ||
005 | 20240426161314.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240426s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA003934179 | ||
035 | |a (EPA)CN117018197 | ||
035 | |a (EPA)88636647 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a LI JING |e verfasserin |4 aut | |
245 | 1 | 0 | |a Application of reagent for promoting DOCK11 expression as medicine for treating neuropathic pain |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2023-11-10, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26 | ||
520 | |a The invention discloses application of a reagent for promoting DOCK11 expression as a medicine for treating neuropathic pain. The research finds that mice suffering from neuropathic pain have obvious mechanical abnormal pain and thermal hyperalgesia, and expression of DOCK11 is closely related to mechanical pain and thermal pain of CCI mice. The overexpressed DOCK11 vector can effectively promote the expression of DOCK11 in the spinal cord and obviously inhibit neuropathic pain at the same time. The research results of the invention provide potential therapeutic targets for clinical treatment of neuropathic pain. | ||
650 | 4 | |a tec | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a DONG BEIBEI |e verfasserin |4 aut | |
700 | 0 | |a LIU BIN |e verfasserin |4 aut | |
700 | 0 | |a ZHAO YUYING |e verfasserin |4 aut | |
700 | 0 | |a WU ZIJUN |e verfasserin |4 aut | |
700 | 0 | |a HAO SHUJING |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 10. Nov. |
773 | 1 | 8 | |g year:2023 |g day:10 |g month:11 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88636647/publication/CN117018197A1?q=CN117018197 |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2023 |b 10 |c 11 |